With Added $25M+ Financing, Nectin Therapeutics Initiates Patient Dosing in Advanced Solid Tumors NTX1088 Phase 1 Trial
Nectin Therapeutics Ltd., (Nectin) a Jerusalem-based biotechnology company developing novel targeted immunotherapies to address resistance to approved immuno-oncology (IO) treatments, started the dosing of the first patient in its Phase…
Continue Reading
With Added $25M+ Financing, Nectin Therapeutics Initiates Patient Dosing in Advanced Solid Tumors NTX1088 Phase 1 Trial